Posted on 14/01/2026
Rayner has secured US Food and Drug Administration (FDA) 510(k) clearance for Sophi, the Swiss-engineered phacoemulsification system set to redefine efficiency for US cataract surgeons. Sophi (Swiss Ophthalmology Innovation) brings a bold new philosophy to the operating room: maximum productivity, without compromise. Packed with features tailored to meet the demands of ASCs, office-based surgery and
Posted on 13/10/2025
FDA approval expands US access to award-winning lens technology Rayner today announced that the US Food and Drug Administration (FDA) has approved its RayOne EMV Toric intraocular lens (IOL) following the successful completion of a pivotal Investigational Device Exemption (IDE) study. The lens is now available to US surgeons seeking to deliver high quality visual
Posted on 27/06/2025
Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, announces today that its RayOne Galaxy and RayOne Galaxy Toric intraocular lenses are now available in Brazil. RayOne Galaxy, which saw a full commercial release in January 2025 following a highly successful multicenter study, sets a new standard for what surgeons can
Posted on 6/05/2025
6 May 2025 Rayner, a global provider of solutions for cataract surgery and the only manufacturer of intraocular lenses (IOLs) in the UK, proudly announces today that it has been honoured with the prestigious King’s Award for Enterprise 2025 for its innovative RayOne EMV increased range of focus IOL. RayOne EMV, which launched in 2020,
Posted on 2/04/2025
02 April 2025 | In response to demand growth, Rayner – a global leader in solutions for cataract surgery – has completed an extensive expansion of its Worthing (UK) production facility, doubling the number of intraocular lenses (IOLs) it can manufacture annually to 4 million. Since opening its purpose-built manufacturing facility in 2017, every Rayner
Posted on 25/03/2025
In a major step toward redefining postoperative care and elevating patient experience, Rayner – a global leader in cataract surgery products – proudly announces the successful completion of its pivotal U.S. dropless cataract surgery study. OMIDRIA (phenylephrine and ketorolac intraocular solution 1% / 0.3%) is the only FDA-approved NSAID for use during cataract surgery, indicated
Posted on 3/02/2025
03.02.25 | Just 18 weeks on from the first implantation, Rayner is delighted to announce that it has now closed recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy intraocular lens in the USA. Developed in collaboration between Rayner, a global manufacturer of cataract surgery solutions, and ophthalmologist Dr João Lyra from
Posted on 23/01/2025
Mississauga, ON | 21 January 2025 Rayner, a global manufacturer of products for cataract surgery based in Worthing, UK, is pleased to announce the approval of RayOne EMV Toric (RAO210T) by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled
Posted on 8/01/2025
Rayner, a global manufacturer of products for cataract surgery, today announces the launch of its redesigned online premium IOL calculator, RayTrace. One of the first online IOL calculation tools, RayTrace has been trusted by surgeons globally since 2008 for the accuracy of its premium IOL (toric, multifocal and supplementary) calculations, and has delivered over 360,000
Posted on 20/11/2024
Rayner, a global manufacturer of products for cataract surgery based in the United Kingdom, has launched a campaign to promote a dropless regimen with OMIDRIA® for postoperative cataract care. According to studies, up to 92% of patients struggle with self-administering postoperative eye drops. Inaccuracy with eye drops poses the risk of inconsistent or missed doses